HIV Vaccines and Passive Immunization
Pipeline PDF • 2021Developing Long-Acting Cures to Accelerate the End of Hepatitis C: Interview with Dr. Dave Thomas
TAGline • 2021Interview questions and editing by Erica Lessem, Bryn Gay, Joelle Dountio Ofimboudem, Annette Gaudino, and Elizabeth Lovinger The World Health Organization set ambitious targets for eliminating the hepatitis C virus (HCV) among the 58 million people living with the disease, but most countries are far from reaching them. How could long-acting technologies, which extend the…
HIV Research Advocacy Fact Sheet
Publication • 2021HIV advocacy laid the foundation for much of the work we do today. This handout was developed in collaboration with the Black AIDS Institute, HIV Vaccine Trials Network, and Southern AIDS Coalition. The handout provides a summary of the history of HIV research advocacy and updates on new HIV advocacy efforts.
New HIV Prevention Research Fact Sheet
Publication • 2021HIV prevention research continues to rapidly evolve. The availability of pre-exposure prophylaxis (PrEP) has necessitated the development of new approaches to testing the efficacy of additional biomedical HIV prevention options. This handout was developed in collaboration with the Black AIDS Institute, HIV Vaccine Trials Network, and Southern AIDS Coalition. The handout provides a summary of…
Broadly Neutralizing Antibodies for HIV Prevention Fact Sheet
Publication • 2021HIV-specific broadly neutralizing antibodies (bNAbs) could have a role in treating, preventing, or even curing HIV. Some HIV-specific bNAbs are already being tested in clinical trials, both for prevention and treatment. This handout was developed in collaboration with the Black AIDS Institute, HIV Vaccine Trials Network, and Southern AIDS Coalition. The handout provides an update…
What’s on the Horizon for Long-Acting Pre-Exposure Prophylaxis (PrEP)? Fact Sheet
Publication • 2021Long-acting pre-exposure prophylaxis (PrEP) will be a groundbreaking HIV prevention tool. The approach provides an option to receive intermittent doses of PrEP instead of taking daily pills. This handout provides an update on the development of long-acting PrEP and future prospects for the approach. The handout was developed in collaboration with the Black AIDS Institute,…
HIV Science Fact Sheet
Publication • 2021HIV science can be difficult to understand. This handout explains some of the unique scientific challenges presented by HIV. The handout was developed in collaboration with the Black AIDS Institute, HIV Vaccine Trials Network, and Southern AIDS Coalition.
PrEPared? Long-Acting PrEP Access in Communities Marginalized by the U.S. Healthcare System
TAGline • 2021By Abraham Johnson The announcement that HIV Prevention Trials Network (HPTN) had two successful studies on long-acting technologies (LAT) to prevent HIV — HPTN 083 and 084 — came with much excitement. Populations most impacted by HIV could possibly have an even greater opportunity to prevent HIV. LATs provide for potentially easier adherence, fewer side…
Terraforming the Policy Landscape to Enable Access to Long-Acting Technologies
TAGline • 2021By Annette Gaudino and Suraj Madoori Let’s Define Terraforming Terraforming — or “earth-shaping” — the transformation of an alien planet into one where humans can live, is probably most familiar to science-fiction fans and Minecraft players. Terraforming is more intensive than landscaping, the term used to describe the need to understand local politics to win…
Know Your CAB: Community Experts Shaping the Long-Acting Technologies Pipeline
TAGline • 2021By Bryn Gay, Joelle Dountio Ofimboudem, and Kenly Sikwese* Meaningful and equitable community engagement is essential to ensuring that long-acting technologies (LATs) clinical research is conducted in ways that are safe, ethical, appropriate, and responsive to community priorities and needs.1 To advance the community engagement work, Treatment Action Group (TAG) and the African Community Advisory…